Instituto Oncologico Dr. Rosell S.L.

At Instituto Oncologico Dr. Rosell S.L. in Barcelona, clinical research is centered on cancer care across a broad range of advanced and hard-to-treat tumors. The studies focus on testing new therapies, combining treatments, and improving how well patients respond to oncology care.

• Advanced and metastatic melanoma, including treatment after prior immunotherapy
• Non-small cell lung cancer, including locally advanced, metastatic, and uncommon mutation subtypes
• Ovarian cancer, especially recurrent, platinum-resistant, and high folate receptor-alpha expressing disease
• Breast cancer, including triple-negative and HER2-positive disease
• Other advanced solid tumors and gynecologic cancers, such as cervical cancer

The research portfolio includes studies designed to evaluate safety, tolerability, and anti-tumor activity, while also comparing newer immunotherapy and targeted approaches with current standards of care.

A major area of activity at this site is melanoma research, with trials in untreated, unresectable, metastatic, and post-treatment settings. These studies are exploring new immune-based strategies to improve disease control and extend progression-free survival.

• Previously untreated, unresectable, or metastatic melanoma
• Advanced melanoma after prior anti-PD-1 therapy
• Neoadjuvant melanoma research
• Comparisons of novel immunotherapy combinations versus established treatment options

The goal of this research is to test whether newer immunotherapy combinations can improve outcomes for patients with difficult-to-treat skin cancer.

The site is also active in lung cancer research, especially for non-small cell lung cancer and small cell lung cancer in advanced or metastatic stages. These trials are evaluating new treatment strategies for patients whose disease has progressed after earlier therapy.

• Advanced and metastatic non-small cell lung cancer
• Post-treatment NSCLC and small cell lung cancer
• Uncommon EGFR mutation-positive lung cancer after surgery
• Studies of targeted agents and combination therapies for better disease control

Research in this area aims to improve treatment effectiveness and expand options for patients with lung cancer who have limited standard choices.

Several trials at this hospital focus on ovarian cancer, including recurrent, platinum-resistant, and advanced disease. The research is designed to better understand how new therapies may help patients whose cancer has become harder to treat.

• Recurrent and advanced ovarian cancer
• Platinum-resistant ovarian cancer
• High folate receptor-alpha expressing disease
• Evaluation of new treatment approaches and safety in gynecologic malignancies

These studies aim to improve response rates, manage side effects, and identify more effective options for gynecologic oncology patients.

The research program also includes breast cancer and broader solid tumor studies, reflecting a strong interest in advanced disease across multiple tumor types. Trials in this area are testing new combinations and novel agents to support better disease control.

• First-line triple-negative breast cancer
• Second-line or later HER2-positive breast cancer
• Locally advanced or metastatic solid tumors
• Studies comparing new therapies with standard treatment approaches

This work is focused on improving outcomes in advanced cancer through innovative treatment strategies and careful assessment of clinical benefit.